Abstract
Staphylococcus aureus is the most common cause of hospital-acquired bacteremia. Due to emergence of antibiotic-resistant strains, these infections present a serious public health threat. In this study, to develop a broadly protective vaccine, we tested whether immune responses induced by several proteins associated with S. aureus toxicity could protect mice from lethal challenge with human clinical S. aureus isolate USA300. We found that the surface protein A (SasA) of S. aureus could protect mice from lethal challenge of the bacteria.
© 2012 The Societies and Blackwell Publishing Asia Pty Ltd.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Bacterial Proteins / administration & dosage
-
Bacterial Proteins / immunology*
-
Female
-
Membrane Proteins / administration & dosage
-
Membrane Proteins / immunology*
-
Mice
-
Mice, Inbred BALB C
-
Staphylococcal Infections / immunology
-
Staphylococcal Infections / mortality
-
Staphylococcal Infections / prevention & control*
-
Staphylococcal Vaccines / administration & dosage
-
Staphylococcal Vaccines / immunology*
-
Staphylococcus aureus / immunology*
-
Staphylococcus aureus / pathogenicity
-
Survival Analysis
Substances
-
Bacterial Proteins
-
Membrane Proteins
-
Staphylococcal Vaccines